NCT04282044 - Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2026

Conditions

Solid Tumor, AdultTriple Negative Breast CancerColorectal CancerHepatocellular CarcinomaOsteosarcomaEpithelial Ovarian CancerGastric CancerNon-small Cell Lung CancerMalignant Melanoma

Interventions

BIOLOGICAL

CRX100 suspension for infusion

A fixed dose of CIK cells combined with the specified dose of CDSR.

COMBINATION_PRODUCT

Fludarabine

25mg/m IV (five doses given from Day -7 until Day -3)

COMBINATION_PRODUCT

Cyclophosphamide

60mg/kg intravenous (IV) (two doses given on Day -7 and -6)

Trial Locations (3)

85258

RECRUITING

HonorHealth Research Institute, Scottsdale

92093

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

94305

RECRUITING

Stanford University, Stanford